Repligen (RGEN) EBITDA (2010 - 2026)

Repligen (RGEN) has 17 years of EBITDA data on file, last reported at -$3.4 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$3.4 million, down 132.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.9 million (up 404.63% YoY), and the FY2025 annual result was $98.9 million, up 345.77% from the prior year.
• EBITDA eased to -$3.4 million in Q1 2026 per RGEN's latest filing, from $14.9 million in the prior quarter.
• Over five years, EBITDA peaked at $69.6 million in Q4 2022 and troughed at -$51.8 million in Q4 2024.
• A 5-year average of $15.0 million and a median of $12.5 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 375.39% in 2024, then jumped 1348.72% in 2025.
• A 5-year view of EBITDA shows it stood at $69.6 million in 2022, then sank by 115.65% to -$10.9 million in 2023, then slumped by 375.39% to -$51.8 million in 2024, then surged by 128.7% to $14.9 million in 2025, then slumped by 123.18% to -$3.4 million in 2026.
• Business Quant data shows RGEN's EBITDA at -$3.4 million in Q1 2026, $14.9 million in Q4 2025, and $12.5 million in Q3 2025.